|Bid||111.50 x 0|
|Ask||112.00 x 0|
|Day's range||109.50 - 113.00|
|52-week range||53.60 - 143.25|
|Beta (5Y monthly)||0.78|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
PharmaEssentia announced that data reflecting five years of experience with ropeginterferon alfa-2b in PV will be presented during ASH 2020.
PharmaEssentia has appointed Raymond Urbanski, M.D., Ph.D., as Head of Clinical Development and Medical Affairs for the U.S. subsidiary.